PRT1309 / PROTEINA - LARVOL DELTA

Proteina, an AI new drug development corporations based on protein interactions, said on the 13th that its obesity and diabetes treatment candidate PRT1309 was selected for an oral presentation at the American Diabetes Association (ADA 2026). (Chosun Biz) - "The company aims to secure in vivo data in the third quarter of this year and validate in a nonhuman primate model by year-end, and plans to pursue an investigational new drug (IND) application in 2027."

IND • Preclinical • Diabetes • Obesity